Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Scientists identify bacteria-based approach against cancer

The body's immune system is the first line of defense against infections like bacteria, viruses or cancers. Some cancers, however, have developed the art of molecular deception to avoid destruction by the body's immune system.

13 Jan 2021

Researchers develop new technique to more efficiently isolate and identify rare T cells

Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are capable of targeting viruses, cancer and other diseases.

12 Jan 2021

Master Regulator proteins control cancer transcriptional identity

Thousands of different genetic mutations have been implicated in cancer, but a new analysis of almost 10,000 patients found that regardless of the cancer's origin, tumors could be stratified in only 112 subtypes and that, within each subtype, the Master Regulator proteins that control the cancer's transcriptional state were virtually identical, independent of the specific genetic mutations of each patient.

11 Jan 2021

MRI frequently underestimates the size of prostate tumors, finds study

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

7 Jan 2021

Mediterranean diet has the potential to effect progression of prostate cancer

In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Researchers apply AI to help physicians customize treatments for patients with oral cancers

Researchers at Case Western Reserve University and partners in the United States and India are applying the investigative and predictive capabilities of artificial intelligence (AI) to help physicians customize treatments for patients with oral squamous cell carcinomas.

5 Jan 2021

Heat treatment during chemotherapy is more effective at destroying cancer cells

Heating up cancer cells while targeting them with chemotherapy is a highly effective way of killing them, according to a new study led by UCL researchers.

5 Jan 2021

Genetic risk score can be used to determine risk of developing prostate cancer

Some racial and ethnic groups suffer relatively more often, and fare worse, from common ailments compared to others. Prostate cancer is one disease where such health disparities occur: risk for the disease is about 75 percent higher, and prostate cancer is more than twice as deadly, in Blacks compared to whites.

4 Jan 2021

Inflammation marker linked to increased fatigue in prostate cancer patients treated with ADT

Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Researchers discover how chromosomal instability allows cancer cells to avoid immune defenses

Cancer cells are known for spreading genetic chaos. As cancer cells divide, DNA segments and even whole chromosomes can be duplicated, mutated, or lost altogether. This is called chromosomal instability, and scientists at Memorial Sloan Kettering have learned that it is associated with cancer's aggressiveness.

28 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Researchers have a promising lead on COVID-19 treatment

By taking a lesson from prostate cancer, researchers now have a promising lead on treatment for COVID-19. Two proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, M.D., Ph.D. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers. They also knew that TMPRSS2 was regulated by the androgen receptor.

21 Dec 2020

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Scientists identify bacteria-based approach against cancer

Researchers develop new technique to more efficiently isolate and identify rare T cells

Master Regulator proteins control cancer transcriptional identity

MRI frequently underestimates the size of prostate tumors, finds study

Mediterranean diet has the potential to effect progression of prostate cancer

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Researchers apply AI to help physicians customize treatments for patients with oral cancers

Heat treatment during chemotherapy is more effective at destroying cancer cells

Genetic risk score can be used to determine risk of developing prostate cancer

Inflammation marker linked to increased fatigue in prostate cancer patients treated with ADT

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Researchers discover how chromosomal instability allows cancer cells to avoid immune defenses

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Researchers have a promising lead on COVID-19 treatment

FDA approves first oral drug for treating adult patients with advanced prostate cancer

No added risks to radiation therapy for cancer patients with COVID-19, says study

RedHill Biopharma announces promising preliminary results from opaganib study

Genomic and immune indicators can help identify prostate cancer patients at high risk of lethal outcomes

Scientist pinpoints genes that promote the growth of prostate cancer cells

New guidelines and standards for the treatment of brain tumor complications

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in